- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04768725
Combined Physical-cognitive Exercise and Dietary Intervention for Postmenopausal Obese Women
February 12, 2023 updated by: Somporn Sungkarat, Chiang Mai University
A Randomized Controlled Trial Investigating the Effects of Combined Physical-cognitive Exercise and Dietary Intervention on Cognitive Performance and Changes in Blood Biomarkers of Postmenopausal Obese Women
This study aims to examine the effects of dietary intervention combined with physical-cognitive exergaming on cognitive performance and circulating biomarkers of obese postmenopausal women.
It is hypothesized that participants will demonstrate significant improvement in cognitive performance and circulating biomarkers after participating in this combined program compared to baseline and the dietary and control groups.
Study Overview
Status
Completed
Conditions
Detailed Description
An association between obesity and cognitive impairment has been consistently reported.
The risk of having dementia in later life is about 74% higher for middle-aged obese individuals than those with normal BMI.
Estrogen deprivation has also been found to impair cognition.
Thus, obese postmenopausal women are likely to be at risk of having cognitive impairment.
The common recommendation for obesity management is dietary and exercise intervention.
Research evidence has demonstrated that either dietary intervention or moderate-vigorous intensity exercise enhance cognitive function in obese adults.
This study aims to examine the effects of 12-week home-based dietary intervention combined with physical-cognitive exergaming on cognitive performance and circulating biomarkers of obese postmenopausal women through a randomised controlled trial.
Participants will be randomly assigned to one of the four groups: 1) dietary intervention 2) combined physical-cognitive exergaming, 3) dietary intervention combined with physical-cognitive exergaming, and 4) control group.
Outcome measures including cognitive performance (i.e.
executive function, episodic memory, attention, language, and global cognition), circulating biomarkers (i.e.
BDNF level, metabolic parameters, inflammation markers, and adiponectin levels) as well as physical performance will be determined at baseline and after 12-week intervention.
Findings from this study may offer a feasible and effective intervention program to improve cognitive performance along with its responsible circulating biomarkers in obese postmenopausal women.
Study Type
Interventional
Enrollment (Actual)
92
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Somporn Sungkarat, PhD
- Phone Number: 6653949249
- Email: somporn.sungkarat@cmu.ac.th
Study Locations
-
-
-
Chiang Mai, Thailand, 50200
- Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 59 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- obese women (body mass index (BMI) ≥ 25 kg/m2 with waist-to-hip ratio (WHR) ≥ 0.80)
- post-menopausal (self-reported menstrual characteristics (last menstruation > 1 year) or confirmed by blood follicular stimulating hormone (FSH) level ( > 20 IU/L) and estradiol level ( ≤ 30 pg/ml))
- sedentary lifestyle (exercise < 1 hr./wk.)
- normal range of the Mental State Examination T10 (MSET10) score
- at least 6 years of education
- own a mobile phone that supports application platform
- able to comply with the study schedule and procedures
Exclusion Criteria:
- have medical conditions that would be unsafe to exercise or have been diagnosed with neurological conditions (e.g. Parkinson's disease, stroke, multiple sclerosis) that affect cognition and mobility
- have weight variation ( > 5 kilogram in 3 months)
- have other dietary restrictions (e.g. vegetarianism and veganism)
- have depressive symptoms defined as a score ≥ 11 on Hospital Anxiety Depression Scale (HADS)
- have an uncorrected visual or hearing impairment
- receive hormonal replacement therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Dietary intervention
Participants will consume a self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day).
|
Intermittent Fasting (IF) [self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)].
|
ACTIVE_COMPARATOR: Physical-cognitive intervention
Participants will perform home-based physical-cognitive training for 60 minutes per session, 3 session a week.
|
Physical-cognitive exercise [60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)].
|
EXPERIMENTAL: Physical-cognitive with dietary intervention
Participants will receive both dietary intervention and physical-cognitive training same as those in the dietary and physical-cognitive intervention groups.
|
Intermittent Fasting (IF) [self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)] combined with physical-cognitive exercise [60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)].
|
NO_INTERVENTION: Control
Participants in the control group will be encouraged to continue their activities and calorie intakes as they usually would.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change from baseline time to complete Trail Making B-A at 12 weeks
Time Frame: 12 weeks
|
Time to complete Trail Making B and A will be recorded in seconds.
The difference between time to complete Trail B and A will be used to index the task switching ability, a subdomain of executive function.
Smaller differences between B-A indicate better switching ability.
|
12 weeks
|
change from baseline Stroop Color and Word score at 12 weeks
Time Frame: 12 weeks
|
In Stroop Color and Word test, the number of items correctly identified in 45 seconds in each condition (i.e.
word, color, color-word) will be recorded.
Then the predicted score will be calculated.
Score will be obtained from the different between the color-word and predicted scores.
Lower scores indicate greater difficulty in inhibiting interference.
|
12 weeks
|
change from baseline Logical Memory score at 12 weeks
Time Frame: 12 weeks
|
In Logical Memory test, participants will be instructed to listen carefully to two stories and remember their contents.
After a 30-delay, they will be asked to freely recall the passages (recall) and respond yes or no to the given questions (recognition).
The possible scores are 0-75.
Higher scores indicate better episodic memory.
|
12 weeks
|
change from baseline Brain-derived neurotrophic factor (BDNF) level at 12 weeks
Time Frame: 12 weeks
|
Level of plasma BDNF will be determined before and after the intervention.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change from baseline Montreal Cognitive Assessment (MoCA) score at 12 weeks
Time Frame: 12 weeks
|
The Montreal Cognitive Assessment will be used to index global cognitive function.
The possible scores are 0-30.
Higher scores indicate better cognitive function.
|
12 weeks
|
change from baseline Verbal Fluency score at 12 weeks
Time Frame: 12 weeks
|
Category fluency subtest (naming test) of Verbal Fluency will be used.
Participants will be asked to produce as many words as possible in 60 seconds.
Higher scores indicate better language ability.
|
12 weeks
|
change from baseline Digit Span score at 12 weeks
Time Frame: 12 weeks
|
In Digit Span test, lists of numbers will be presented orally to participants.
They are asked to repeat the numbers immediately in ascending (forward) or reverse (backward) numerical order.
The possible scores are 0-28.
Higher scores indicate better attention.
|
12 weeks
|
change from baseline plasma adiponectin levels at 12 weeks
Time Frame: 12 weeks
|
Level of plasma adiponectin will be determined before and after intervention.
|
12 weeks
|
change from baseline plasma Interleukin 6 (IL-6) levels at 12 weeks
Time Frame: 12 weeks
|
Level of plasma IL-6 will be determined before and after intervention.
|
12 weeks
|
change from baseline insulin resistance levels at 12 weeks
Time Frame: 12 weeks
|
Level of insulin resistance will be assessed using the homeostasis model assessment (HOMA-IR) index [fasting glucose (mg/dL) X fasting insulin (µU/mL) / 405].
|
12 weeks
|
change from baseline Six-minute walk distance at 12 weeks
Time Frame: 12 weeks
|
The distance (in meters) participants walked in 6 minutes will be determined.
Longer distance indicates better cardiorespiratory fitness.
|
12 weeks
|
change from baseline 30 seconds Chair Stand Test at 12 weeks
Time Frame: 12 weeks
|
The number of repetitions participants could perform sit-to-stand will be recorded.
Higher number of repetitions indicates greater lower-body strength.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 26, 2021
Primary Completion (ACTUAL)
December 3, 2022
Study Completion (ACTUAL)
December 5, 2022
Study Registration Dates
First Submitted
February 5, 2021
First Submitted That Met QC Criteria
February 22, 2021
First Posted (ACTUAL)
February 24, 2021
Study Record Updates
Last Update Posted (ESTIMATE)
February 14, 2023
Last Update Submitted That Met QC Criteria
February 12, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMS-PT CMU 2564
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Dietary intervention
-
University of ViennaCompletedEndotoxemia | Dietary HabitsAustria
-
Azienda Ospedaliero-Universitaria CareggiRecruiting
-
Brown UniversityNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Brown UniversityNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University Hospital, Strasbourg, FranceRecruitingDigestive Cancer | UndernourishedFrance
-
Josephine Ford Cancer CenterNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of South CarolinaAcademy of Nutrition and DieteticsCompleted
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedCaloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast CancerBreast Carcinoma | Endometrial Carcinoma | Prostate CarcinosarcomaUnited States